The global electromyography devices market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 2.4 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 38.0% in 2025. The market is driven by the increasing prevalence of neuromuscular and peripheral nerve disorders, including neuropathies, carpal tunnel syndrome, radiculopathy, and motor neuron diseases.
Growing adoption of EMG in neurological diagnosis, rehabilitation, sports medicine, and intraoperative nerve monitoring, coupled with advancements in portable, wireless, and high-density EMG systems, is further supporting market growth. The increasing prevalence of neuromuscular and peripheral nerve disorders, including diabetic neuropathy, carpal tunnel syndrome, radiculopathy, myopathies, and motor neuron diseases, is driving demand for electromyography (EMG) devices. EMG and nerve conduction studies are widely used to assess nerve and muscle function, localize nerve damage, determine disease severity, and differentiate between nerve and muscle disorders.
The growing burden of neurological and neuromuscular disorders is increasing the need for accurate and functional diagnostic testing, supporting demand for electromyography (EMG) devices. EMG, often performed alongside nerve conduction studies (NCS), helps clinicians evaluate nerve and muscle function, identify peripheral nerve damage, differentiate nerve from muscle disorders, and diagnose conditions such as peripheral neuropathy, carpal tunnel syndrome, radiculopathy, and motor neuron disorders.
For instance, in March 2025, the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) identifies EMG and nerve-conduction studies as electrodiagnostic tests used to evaluate a broad range of neurological and neuromuscular conditions. Its recommended policy includes specific diagnostic indications and ICD-10-CM diagnoses for needle EMG and nerve conduction studies.
In addition, the U.S. National Institute of Neurological Disorders and Stroke (NINDS) continues to identify EMG and NCS as diagnostic procedures used in evaluating neurological symptoms and disorders. The NINDS neurological diagnostic testing resource was updated in March 2026, underscoring the continued role of electrodiagnostic testing in contemporary neurological practice.
Furthermore, technological advancements are driving the electromyography (EMG) devices market by enabling the development of wireless, portable, high-density, multi-channel, and multimodal EMG systems that deliver higher-quality signals and greater flexibility. For example, newer systems such as Noraxon’s Ultium EMG support sampling rates of up to 4,000 Hz, integrated inertial measurement units (IMUs), real-time synchronization, and wireless data transmission, enabling simultaneous assessment of muscle activity and movement.
The integration of digital software, automated signal processing, mobile connectivity, and EMG-triggered rehabilitation technologies is also expanding applications beyond conventional neurological diagnostics into rehabilitation, biomechanics, sports medicine, and prosthetics. The FDA recognizes EMG-triggered powered exercise equipment for muscle re-education and rehabilitation, while its updated recognition of IEC 60601-2-40 (2024 edition) reflects continuing standardization of modern electromyograph and evoked-response equipment.
Growing adoption of EMG in neurological diagnosis, rehabilitation, sports medicine, and intraoperative nerve monitoring, coupled with advancements in portable, wireless, and high-density EMG systems, is further supporting market growth. The increasing prevalence of neuromuscular and peripheral nerve disorders, including diabetic neuropathy, carpal tunnel syndrome, radiculopathy, myopathies, and motor neuron diseases, is driving demand for electromyography (EMG) devices. EMG and nerve conduction studies are widely used to assess nerve and muscle function, localize nerve damage, determine disease severity, and differentiate between nerve and muscle disorders.
The growing burden of neurological and neuromuscular disorders is increasing the need for accurate and functional diagnostic testing, supporting demand for electromyography (EMG) devices. EMG, often performed alongside nerve conduction studies (NCS), helps clinicians evaluate nerve and muscle function, identify peripheral nerve damage, differentiate nerve from muscle disorders, and diagnose conditions such as peripheral neuropathy, carpal tunnel syndrome, radiculopathy, and motor neuron disorders.
For instance, in March 2025, the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) identifies EMG and nerve-conduction studies as electrodiagnostic tests used to evaluate a broad range of neurological and neuromuscular conditions. Its recommended policy includes specific diagnostic indications and ICD-10-CM diagnoses for needle EMG and nerve conduction studies.
In addition, the U.S. National Institute of Neurological Disorders and Stroke (NINDS) continues to identify EMG and NCS as diagnostic procedures used in evaluating neurological symptoms and disorders. The NINDS neurological diagnostic testing resource was updated in March 2026, underscoring the continued role of electrodiagnostic testing in contemporary neurological practice.
Furthermore, technological advancements are driving the electromyography (EMG) devices market by enabling the development of wireless, portable, high-density, multi-channel, and multimodal EMG systems that deliver higher-quality signals and greater flexibility. For example, newer systems such as Noraxon’s Ultium EMG support sampling rates of up to 4,000 Hz, integrated inertial measurement units (IMUs), real-time synchronization, and wireless data transmission, enabling simultaneous assessment of muscle activity and movement.
The integration of digital software, automated signal processing, mobile connectivity, and EMG-triggered rehabilitation technologies is also expanding applications beyond conventional neurological diagnostics into rehabilitation, biomechanics, sports medicine, and prosthetics. The FDA recognizes EMG-triggered powered exercise equipment for muscle re-education and rehabilitation, while its updated recognition of IEC 60601-2-40 (2024 edition) reflects continuing standardization of modern electromyograph and evoked-response equipment.
Global Electromyography Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global electromyography devices market report based on product, technology, clinical application, end use, and region:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Hardware & Systems
- Stationary / Standalone EMG Systems
- Portable / Handheld EMG Systems
- Wearable & Wireless EMG Patches
- Integrated Systems (EMG-EEG / EMG-EP / EMG-IONM)
- Electrodes & Sensors
- Surface Electrodes
- Needle Electrodes
- High-Density EMG Electrode Arrays
- Accessories
- Patient Cables & Lead Wires
- Junction Boxes & Connectors
- Conductive Gels & Skin Preparation Products
- Replacement Parts
- Software
- Signal Acquisition Software
- Analysis & Reporting Software
- AI-assisted Diagnostic Software
Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Surface EMG
- Intramuscular / Needle EMG (iEMG)
- High-Density EMG (HD-EMG)
- Wireless / Wearable EMG
Clinical Application Outlook (Revenue, USD Million, 2021 - 2033)
- Neuromuscular Disorder Diagnosis
- Intraoperative Neuromonitoring (IONM)
- Physical Medicine & Rehabilitation
- Orthopedics & Sports Medicine
- Prosthetics & Human Movement Analysis
- Research & Academia
End Use Outlook (Revenue, USD Million; 2021 - 2033)
- Hospitals & Surgical Centers
- Ambulatory Surgical Centers
- Neurology & Electrodiagnostic Clinics
- Rehabilitation Centers
- Academic & Research Institutions
- Home Healthcare & Remote Monitoring
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Electromyography Devices Market Variables, Trends & Scope
Chapter 4. Electromyography Devices Market: Product Estimates & Trend Analysis
Chapter 5. Electromyography Devices Market: Technology Estimates & Trend Analysis
Chapter 6. Electromyography Devices Market: Clinical Application Estimates & Trend Analysis
Chapter 7. Electromyography Devices Market: End Use Estimates & Trend Analysis
Chapter 8. Electromyography Devices Market: Regional Estimates & Trend Analysis by Product, Clinical Application, Technology, and End Use
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Natus Medical Incorporated (ArchiMed)
- NIHON KOHDEN CORPORATION
- Cadwell Industries Inc.
- Medtronic
- Neurosoft LLC
- Noraxon
- Delsys
- Cometa srl
- Artinis Medical Systems
- Biometrics Ltd
- EB Neuro S.p.A. (Hanix Group)
- Allengers
